VRDN Sep 2024 20.000 call
| Previous close | 2.9500 |
| Open | 3.0000 |
| Bid | 0.7500 |
| Ask | 2.6500 |
| Strike | 20.00 |
| Expiry date | 2024-09-20 |
| Day's range | 2.9500 - 3.0000 |
| Contract range | N/A |
| Volume | |
| Open interest | 33 |
Business WireViridian Therapeutics Announces Details of Subcutaneous VRDN-003 Phase 3 Clinical Program for Patients with Active and Chronic Moderate-to-Severe Thyroid Eye Disease
WALTHAM, Mass., June 11, 2024--Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today reported details of its plans to initiate a phase 3 clinical trial program for its SC VRDN-003 product candidate for patients with moderate-to-severe TED.
Business WireViridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WALTHAM, Mass., June 06, 2024--Viridian Therapeutics, Inc. (Nasdaq: VRDN) (the "company" or "Viridian"), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced that a majority of the independent directors serving on the Compensation Committee of the company’s Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 450,000 shares of the company’s common stock to two
Business WireViridian Therapeutics Announces Participation in Upcoming June Investor Conferences
WALTHAM, Mass., May 31, 2024--Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced that senior management will participate in the following upcoming investor conferences in June:
